| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS20034276 | HPV | ENSG00000179546.5 | protein_coding | HTR1D | No | No | 3352 | P28221 |
| TVIS20034277 | HPV | ENSG00000179546.5 | protein_coding | HTR1D | No | No | 3352 | P28221 |
| TVIS20034280 | HPV | ENSG00000179546.5 | protein_coding | HTR1D | No | No | 3352 | P28221 |
| TVIS20047208 | HPV | ENSG00000179546.5 | protein_coding | HTR1D | No | No | 3352 | P28221 |
| TVIS20034278 | HPV | ENSG00000179546.5 | protein_coding | HTR1D | No | No | 3352 | P28221 |
| TVIS20034282 | HPV | ENSG00000179546.5 | protein_coding | HTR1D | No | No | 3352 | P28221 |
| TVIS20034283 | HPV | ENSG00000179546.5 | protein_coding | HTR1D | No | No | 3352 | P28221 |
| TVIS20047211 | HPV | ENSG00000179546.5 | protein_coding | HTR1D | No | No | 3352 | P28221 |
| TVIS20047209 | HPV | ENSG00000179546.5 | protein_coding | HTR1D | No | No | 3352 | P28221 |
| TVIS20034281 | HPV | ENSG00000179546.5 | protein_coding | HTR1D | No | No | 3352 | P28221 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | HTR1D |
|---|---|
| DrugBank ID | DB00952 |
| Drug Name | Naratriptan |
| Target ID | BE0000659 |
| UniProt ID | P28221 |
| Regulation Type | agonist |
| PubMed IDs | 10563228; 11897116; 8741180; 11752352; 12010764; 14725972; 14728705; 20687618; 10410185; 11152011; 12463278; 16389295 |
| Citations | Hargreaves RJ, Shepheard SL: Pathophysiology of migraine--new insights. Can J Neurol Sci. 1999 Nov;26 Suppl 3:S12-9.@@Donaldson C, Boers PM, Hoskin KL, Zagami AS, Lambert GA: The role of 5-HT1B and 5-HT1D receptors in the selective inhibitory effect of naratriptan on trigeminovascular neurons. Neuropharmacology. 2002 Mar;42(3):374-85.@@Pauwels PJ, Colpaert FC: Selective antagonism of human 5-HT1D and 5-HT1B receptor-mediated responses in stably transfected C6-glial cells by ketanserin and GR 127,935. Eur J Pharmacol. 1996 Apr 4;300(1-2):141-5.@@Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.@@Akin D, Onaran HO, Gurdal H: Agonist-directed trafficking explaining the difference between response pattern of naratriptan and sumatriptan in rabbit common carotid artery. Br J Pharmacol. 2002 May;136(2):171-6.@@Hoskin KL, Lambert GA, Donaldson C, Zagami AS: The 5-hydroxytryptamine1B/1D/1F receptor agonists eletriptan and naratriptan inhibit trigeminovascular input to the nucleus tractus solitarius in the cat. Brain Res. 2004 Feb 13;998(1):91-9.@@Boers PM, Donaldson C, Zagami AS, Lambert GA: Naratriptan has a selective inhibitory effect on trigeminovascular neurones at central 5-HT1A and 5-HT(1B/1D) receptors in the cat: implications for migraine therapy. Cephalalgia. 2004 Feb;24(2):99-109.@@Johnston MM, Rapoport AM: Triptans for the management of migraine. Drugs. 2010 Aug 20;70(12):1505-18. doi: 10.2165/11537990-000000000-00000.@@Dulli DA: Naratriptan: an alternative for migraine. Ann Pharmacother. 1999 Jun;33(6):704-11.@@Tfelt-Hansen P, De Vries P, Saxena PR: Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs. 2000 Dec;60(6):1259-87.@@Massiou H: Naratriptan. Curr Med Res Opin. 2001;17 Suppl 1:s51-3.@@Lambert GA: Preclinical neuropharmacology of naratriptan. CNS Drug Rev. 2005 Autumn;11(3):289-316. |
| Groups | Approved; Investigational |
| Direct Classification | 3-alkylindoles |
| SMILES | CNS(=O)(=O)CCC1=CC2=C(NC=C2C2CCN(C)CC2)C=C1 |
| Pathways | |
| PharmGKB | PA450597 |
| ChEMBL | CHEMBL1278 |
